Zofran Birth Defect Lawsuit Joins Others Alleging Drug Caused Infant’s Heart Defects

October 27, 2015 – – ZofranLegal.com reports on another Zofran lawsuit filed against pharmaceutical giant GlaxoSmithKline, by parents from Massachusetts who claim their child’s exposure to the drug while in utero ultimately caused her to develop serious congenital heart defects.

Their complaint was filed on July 22, 2015, and joins many other similar lawsuits. It is logged under case number 1:15-CV-13002-FDS in the U.S. District Court for the District of Massachusetts.

At this time, it is noted that at least 60 other lawsuits relating to Zofran use during pregnancy and subsequent birth defects have been filed across the United States. They have recently been consolidated to form multidistrict litigation, enabling a more speedy and smooth litigation process, and helping to eliminate duplicate discovery.

The drug, which is faced with many complaints after being marketed and prescribed as an “off label” treatment for morning sickness, has come under much scrutiny. It was approved by the U.S. Food and Drug Administration for treatment of patients experiencing episodes of extreme nausea and vomiting after undergoing chemotherapy, radiation, or anesthesia procedures. The drug, however, was never approved to treat pregnant women struggling with morning sickness. Despite this fact, it was marketed as a treatment for expectant mothers experiencing nausea by GSK.

In this particular lawsuit, plaintiffs allege that their daughter was born with two serious heart defects: transposition of the great vessels, and pulmonary stenosis. The baby was exposed to Zofran while in utero, during the first trimester, a time when the heart does most of its developing. Immediately after her birth, the infant was rushed out of the delivery room and away from her parents.

According to the child’s parents, when born, her skin was a blue color. This signaled to the physicians and support staff that the child may have a condition called cyanosis, which is caused by poor circulation and generally indicates that severe heart defects are present. The doctors performed an echocardiogram on the infant, which revealed transposition of the great vessels (also known as arteries,) indicating that her main arteries had developed in reversed positions.

This reversal caused the baby’s blood to loop incorrectly, and therefore did not allow it to nourish her organs or body tissue. The young child required operation within 5 days of birth due to the severity of this condition.

Today, the girl, who is now seven years old, continues to require substantial monitoring due to her condition. Her cardiologist appointments, as parents report, were recently moved from annual visits to bi-annual ones. She struggles with learning difficulties and other issues associated with her condition that are limiting to her abilities.

Across the United States, parents continue filing Zofran lawsuits. The attorneys at Monheit Law are currently providing free consultations to anyone who has given birth to a child with defects after using Zofran while pregnant. Those who have may be entitled to legal action and compensation.

For additional information on this topic or to ask questions, please contact attorney Michael Monheit by calling 877-620-8411 today.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60004887